Dr. Dan Skovronsky

Equibles does not estimate personal net worth.

Get an email with a short summary when ELI LILLY & Co publishes a filing, an earnings call transcript or a press release.

Get LLY alerts

About Dr. Dan Skovronsky

Dr. Dan Skovronsky has spoken on 2 earnings calls across 1 company, most recently for ELI LILLY & Co on October 29, 2026. ELI LILLY & Co is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at ELI LILLY & Co includes Juan Luciano (CEO), David Ricks (Chairman and Board Member), Kimberly Johnson (COO) and 6 others.

Dr. Dan Skovronsky on recent calls

“Since our last earnings call, we've made progress across Lilly R&D. I'll begin in cardiometabolic health by recapping our most recent Phase III readout from our GIP GLP-1 glucagon triple agonist, retitrutide.”

Other, Q3 2026 Earnings Call · October 29, 2026

“Since our last earnings call, we've been busy with portfolio progression and significant business development in each of our major therapeutic areas. I'll share updates by area, beginning with cardiometabolic health.”

Other, ELI LILLY & Co Q1 FY2026 Earnings Call · April 30, 2026